Evidence mapPaperPMID 39180225Full record

ReviewPigment cell & melanoma research2025

X and Y Differences in Melanoma Survival Between the Sexes.

Peter Hersey, Hsin-Yi Tseng, Sara Alavi, Jessamy Tiffen

Abstract readReview
In one paragraph

Review in Pigment cell & melanoma research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Peter HerseyMelanoma Immunology and Oncology Program, the Centenary Institute, University of Sydney, Camperdown, New South Wales, Australia.ORCID 0000-0002-3064-737X
Hsin-Yi TsengMelanoma Epigenetics Lab, the Centenary Institute, University of Sydney, Camperdown, New South Wales, Australia.ORCID 0000-0002-7499-7515
Sara AlaviMelanoma Epigenetics Lab, the Centenary Institute, University of Sydney, Camperdown, New South Wales, Australia.ORCID 0000-0003-4716-8137
Jessamy TiffenMelanoma Institute Australia, Sydney, New South Wales, Australia.ORCID 0000-0003-1086-3953

Funding

Australian Melanoma Research FoundationCancer Council NSWCancer Institute NSW
6 · The paper itself

Abstract

Marked differences in survival from melanoma are noted between men and women that cannot be accounted for by behavioral differences. We and others have provided evidence that this difference may be due to increased expression of immune-related genes from the second X chromosome because of failure of X inactivation. In the present review, we have examined evidence for the contrary view that survival differences are due to weaker immune responses in males. One reason for this may be the loss of Y chromosomes (LOY), particularly in older males. The genes involved may have direct roles in immune responses or be noncoding RNAs that regulate both sex and autosomal genes involved in immune responses or tumor growth. Loss of the KDM6C and KDM5D demethylases appeared to common genes involved. The second factor appears to be the activation of androgen receptors (AR) on melanoma cells that increase their invasiveness and growth. Induction of T-cell exhaustion by AR that limits immune responses against melanoma appeared a common finding. The development of treatments to overcome effects related to gene loss on Y poses challenges, but several avenues related to AR signaling appear worthy of further study in the treatment of metastatic disease.

Indexed as

Chromosomes, Human, XChromosomes, Human, YMelanomaSkin NeoplasmsAnimalsFemaleHumansMaleReceptors, AndrogenSex FactorsReceptors, Androgenandrogen receptorsdemethylasesKDM5DKDM6C noncoding RNAsloss of Y chromosomemelanomaoverall survivalPRC1 complexesX chromosome

Identifiers

PMID39180225
PMCPMC11681842

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.